Teva/Ivax merger
This article was originally published in The Tan Sheet
Executive Summary
FTC continues to review the consent order signed by Teva Pharmaceutical and Ivax; however, the firms have "no reason to believe that the acceptance will not be forthcoming shortly," the two firms announce Jan. 10. The acquisition of Ivax by Teva is expected close on the third business day following the firms' announcement that FTC has accepted the order, they add. The deal previously was expected to close Jan. 12, and now is anticipated to close "later this month." The acquisition was announced in August (1"The Tan Sheet" Aug. 1, 2005, p. 11)...
You may also be interested in...
Teva Broadens Private Label OTC Offerings With Ivax Acquisition
Teva's planned acquisition of Ivax adds a wide range of private label OTCs to the firm's generic drug portfolio
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.